Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:34 AM
Ignite Modification Date:
2025-12-25 @ 12:34 AM
NCT ID:
NCT00003467
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed recurrent primary low grade glioma including:
* Fibrillary astrocytoma
* Oligodendroglioma
* Mixed glioma
* Evidence of measurable enhancing or non-enhancing CNS neoplasm on MRI
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* Karnofsky 60-100%
Life expectancy:
* Not specified
Hematopoietic:
* Hematocrit greater than 29%
* Absolute neutrophil count greater than 1500/mm\^3
* Platelet count greater than 125,000/mm\^3
Hepatic:
* SGOT less than 1.5 times upper limit of normal (ULN)
* Bilirubin less than 1.5 times ULN
Renal:
* Creatinine less than 1.5 mg/dL
* BUN less than 25 mg/dL
Other:
* Not pregnant or nursing
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* At least 4 weeks since prior chemotherapy unless disease progression
Endocrine therapy:
* Concurrent corticosteroids allowed (must be on stable dose for 1 week prior to study)
* No concurrent immunosuppressive agents
Radiotherapy:
* At least 4 weeks since prior radiotherapy unless disease progression
Surgery:
* Not specified
Other:
* No other concurrent medication that may interfere with study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00003467
Study Brief:
Protocol Section:
NCT00003467